PTPRD and neoplasm: Excluding mutations appearing in intermediate or normal cells, we partitioned the remaining mutations in two sets based on their appearance in metastatic cells, denoted as M-mutations, the mutations appearing at most once in primary tumor cells (mutations in LINGO2, IL7R, LINGO2, SPEN, F8, LAMB4, PIK3CG, LINGO2, PTPRD, FUS, NR4A3, HELZ, PRKCB) and P-mutations (mutations in APC, FHIT, ATP7B, LINGO2, LRP1B, CHN1, IL21R, APC, TOX, MN1, MYH11, TP53, NRAS, CDK4, LINGO2, STRN).